Acquiring Company
Pelthos Therapeutics
Acquired Company
Castle Creek Biosciences, Inc
DurhamExtonBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiotechnologyHealth CareDescription
Pelthos Therapeutics and Castle Creek Biosciences have entered into a definitive agreement under which Castle Creek will merge with Pelthos. The combined company will operate as Pelthos Therapeutics Inc. and continue trading on the NYSE American under PTHS. The deal adds Castle Creek's late-stage D-Fi franchise for dystrophic epidermolysis bullosa to Pelthos' dermatology portfolio.
Quick answer
Pelthos Therapeutics is acquiring Castle Creek Biosciences, Inc, announced October 30, 2026. Pelthos Therapeutics is based in Durham, North Carolina, United States.
- How much did Pelthos Therapeutics pay for Castle Creek Biosciences, Inc?
- The deal value was not disclosed.
- What does Pelthos Therapeutics do?
- Pelthos Therapeutics Inc. was formerly known as Chromocell Therapeutics Corp. Pelthos Therapeutics specializes in developing treatments for molluscum contagiosum infections.
- Where are Pelthos Therapeutics and Castle Creek Biosciences, Inc based?
- Pelthos Therapeutics is based in Durham, North Carolina, United States. Castle Creek Biosciences, Inc is based in Exton, Pennsylvania, United States.
- Who are the decision-makers at Pelthos Therapeutics?
- Fundz holds 4 contacts at Pelthos Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Nuformix proposes merger with Biovara (November 11, 2026)
- Abeona Therapeutics to Acquire APT-1011 Assets from Ellodi Pharmaceuticals (November 9, 2026)
- Acrivon Therapeutics Acquires Aqilion’s Drug Development Programs (November 6, 2026)
- Indivior Pharmaceuticals Completes Acquisition of Supernus Pharmaceuticals (November 2, 2026)
- Ambrose Healthcare acquires AM-Pharma for rare disease (October 20, 2026)
- Merck KGaA to acquire Silence Therapeutics for $1.3B, $1.3B (October 19, 2026)
Who to call at Pelthos Therapeutics, and when
When Pelthos Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Pelthos Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Pelthos Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pelthos Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pelthos Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Castle Creek Biosciences, Inc?
Castle Creek Biosciences, Inc was acquired by Pelthos Therapeutics, based in Durham. The deal was reported on October 30, 2026. Pelthos Therapeutics Inc. was formerly known as Chromocell Therapeutics Corp. Pelthos Therapeutics specializes in developing treatments for molluscum contagiosum infections. Pelthos Therapeutics is publicly traded (PTHS) and operates in Biotechnology.
When did Pelthos Therapeutics acquire Castle Creek Biosciences, Inc?
Pelthos Therapeutics's acquisition of Castle Creek Biosciences, Inc was reported on October 30, 2026. Pelthos Therapeutics and Castle Creek Biosciences have entered into a definitive agreement under which Castle Creek will merge with Pelthos. The combined company will operate as Pelthos Therapeutics Inc. and continue trading on the NYSE American under PTHS. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Castle Creek Biosciences, Inc do?
Castle Creek Biosciences is a late-stage company developing re-dosable gene therapies. It is preparing to launch a pivotal clinical trial of its lead candidate, D-Fi, for patients with dystrophic epidermolysis bullosa (DEB). It is privately held, operating in Biotechnology, and is based in Exton.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.